The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.
 
Melissa Lynne Johnson
Consulting or Advisory Role - Astellas Pharma (I); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Genentech/Roche (Inst); Otsuka (I)
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Genmab (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Janssen (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Stem CentRx (Inst); Tarveda Therapeutics (Inst)
 
Tim Meyer
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Daniel M. Halperin
Consulting or Advisory Role - Abbvie; Ipsen; Novartis
Research Funding - Dicerna (Inst); Genentech/Roche (Inst); Ipsen (Inst); Novartis (Inst); Tarveda Therapeutics (Inst); Thermo Fisher Scientific (Inst)
 
Antonio Tito Fojo
Consulting or Advisory Role - Cerulean Pharma
Patents, Royalties, Other Intellectual Property - Very small amount of royalties from the federal government from a long-standing agreement on taxol. This has now ended.
 
Natalie Cook
No Relationships to Disclose
 
Lawrence Scott Blaszkowsky
No Relationships to Disclose
 
Benjamin L. Schlechter
No Relationships to Disclose
 
James C. Yao
No Relationships to Disclose
 
Yannis Jemiai
Employment - Cytel
Leadership - Cytel
Stock and Other Ownership Interests - Cytel
 
Kristina Kriksciukaite
No Relationships to Disclose
 
Marsha Jones
No Relationships to Disclose
 
Nneamaka Ezema
Employment - Symphony Evolution
Travel, Accommodations, Expenses - Symphony Evolution
 
Laura Mei
Employment - Alexion Pharmaceuticals; Tarveda Therapeutics
Stock and Other Ownership Interests - Alexion Pharmaceuticals
Consulting or Advisory Role - Aeglea Biotherapeutics; HemoShear; Proteostasis Therapeutics; Seres Therapeutics
 
Leila Alland
Employment - Tarveda Therapeutics
Leadership - Tarveda Therapeutics
Stock and Other Ownership Interests - Tarveda Therapeutics
Patents, Royalties, Other Intellectual Property - One of multiple signatories on various patents filed by my current employer.
Travel, Accommodations, Expenses - Tarveda Therapeutics
 
Matthew H. Kulke
Consulting or Advisory Role - Ipsen; Lexicon; Novartis
Research Funding - Ipsen